Multicenter phase 2 trial of coadministration of CD19- and CD22-directed CAR T-cell therapy in childhood B-cell ALL

A multicenter phase 2 trial evaluated safety and efficacy of coadministration of CD19- and CD22-directed CAR T-cells in pediatric patients (age ≤ 20 years) with refractory disease or high-risk hematologic or isolated extramedullary relapse of B-cell ALL. The 12-month event-free survival was 69.2% in patients treated for hematologic relapse without consolidative allogeneic hematopoietic cell transplantation, 95% for isolated testicular relapse, and 68.8% for isolated CNS relapse. The authors conclude that CD19-/CD22-CAR T-cell therapy achieved relatively durable remission in children with R/R ALL, including those with isolated or combined extramedullary relapse.